Abbott’s HUMIRA® (adalimumab) approved in Europe for treatment of ulcerative colitis (UC)
11 April 2012 | By
The European Commission has approved HUMIRA®...
List view / Grid view
11 April 2012 | By
The European Commission has approved HUMIRA®...
27 February 2012 | By Novartis
The European Commission has approved an update to the Glivec® (imatinib)* label...
21 February 2012 | By AstraZeneca
Marketing authorisation for CAPRELSA® (vandetanib) granted...
6 February 2012 | By Chamberlain Healthcare PR
The European Commission has approved the use of Galvus® (vildagliptin)...
5 December 2011 | By Novartis
The European Commission has approved Galvus® (vildagliptin) (50 mg once a day) for the treatment of type 2 diabetes patients with moderate or severe renal impairment...
29 November 2011 | By AstraZeneca
The European Commission has granted marketing authorisation for KOMBOGLYZE™...
28 November 2011 | By Daniel J Edelman Ltd
The European Commission has granted marketing authorisation for EDURANT® (rilpivirine)...
28 November 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Eviplera®...
17 November 2011 | By GlaxoSmithKline
GSK welcomes the EC’s commitment...
15 November 2011 | By Amgen
The EC has approved a variation to the marketing authorization for Vectibix®...
3 October 2011 | By Ogilvy Healthworld UK Limited
Pfizer announce the launch of BeneFIX® with Room Temperature Storage (RTS)....
8 September 2011 | By Novartis
The European Commission has approved Votubia® (everolimus) tablets* for the treatment of patients aged 3 years and older...
5 September 2011 | By Novartis
The European Commission has approved Afinitor® (everolimus) tablets...
25 August 2011 | By Boehringer Ingelheim
Marketing Authorisation from the European Commission for Trajenta® (linagliptin)...
4 August 2011 | By Ogilvy Healthworld UK Limited
Pradaxa®1 (dabigatran etexilate) approved...